Frontlight ResearchEarly access
Active, not recruitingPhase 1/2
Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder
Key facts
- Who runs it
- Portland VA Research Foundation, Inc
- Where
- Vancouver, United StatesSee the site
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 1/2
- People taking part
- 30 people, planned
- Started
- 7 Jul 2022
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 2 groups
- Treatments tested
- Psilocybin
- Treatment-as-usual
- Record updated
- 22 April 2026
Who can take part
- Age
- 25 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (13)Hide the full registry criteria
Who can take part
- United States military Veteran
- Moderate to severe methamphetamine use disorder using the DSM-V diagnostic criteria
- Desire to cease or reduce methamphetamine use
Who cannot take part
- Taking certain medications that may interact with psilocybin
- Have uncontrolled hypertension or clinically significant cardiovascular disease
- History of seizure disorder in adulthood
- CNS metastases or symptomatic central nervous system (CNS) infection
- Poorly controlled diabetes mellitus
- History of any primary persistent psychotic disorder, including schizophrenia, schizoaffective disorder, bipolar disorder with psychosis, major depressive disorder with psychosis, or schizophreniform disorder
- History of bipolar I disorder
- Current eating disorder with active purging
- History of hallucinogen use disorder
- Pregnant or breast feeding
Where in United States
- Portland VA Health Care SystemVancouver, United States
About the trial
What the trial wants to find out
This is a proof-of-concept randomized clinical trial of psilocybin-enhanced psychotherapy versus treatment-as-usual among individuals being treated for methamphetamine use disorder.
The 2 groups in the trial
- Psilocybin-enhanced psychotherapyTreatment being tested
Psilocybin will be administered twice (25mg \& 30mg two weeks apart) in addition to a 6-week psychotherapy protocol while admitted to a residential rehabilitation treatment program.
Treatment: Psilocybin and Treatment-as-usual
- Treatment-as-UsualOther group
Treatment-as-usual while admitted to a residential rehabilitation treatment program.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 22 April 2026